Q&A: Lonza's Christian Dowdeswell talks HPAPIs and the Oasmia deal
The mRNA boom has been beneficial for CDMOs, and Lonza is no different. It’s upgraded three of its sites — two in Europe and one in New Hampshire — since landing deals with Moderna to produce the biotech’s Covid-19 vaccine, and is being considered one of the bigwigs that will be responsible for more than half of the world’s drug capacity by 2025.
And last week, the Swiss drugmaker inched closer to that goal, when it announced the completion of a massive upgrade at a Nansha, China manufacturing site. The upgrade will expand the company’s ability to manufacture highly potent active pharmaceutical ingredients, and a deal has already been signed with Oasmia Pharmaceuticals to make its ovarian cancer drug candidate. That will start later this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.